Form Type: 4

SEC EDGAR Link
Acccession Number:0001019056-19-000476
Date:2019-08-12
Issuer: APTEVO THERAPEUTICS INC. (APVO)
Original Submission Date:

Reporting Person:

EL-HIBRI FUAD
2401 4TH AVENUE, SUITE 1050
SEATTLE, WA 98121

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2019-08-12 P 100,000 a $0.76 1,124,536 direct
COMMON STOCK 0 $0.00 2,172,125 indirect
COMMON STOCK 0 $0.00 762,077 indirect
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 the transaction reported on this form 4 was made by the reporting person pursuant to a trading plan adopted on may 31, 2019 that is intended to comply with rule 10b5-1(c) under the securities exchange act of 1934, as amended.
f2 the price reported represents the weighted average price of shares purchased in multiple transactions at prices ranging from $0.4999 to $0.8000 per share. the reporting person will provide to the issuer, any security holder of the issuer or the sec staff, upon request, information regarding the number of shares purchased at each price within the range.
f3 the reporting person's wife, individually, and the reporting person and his wife, as tenants by the entirety, collectively hold an aggregate 40.65% equity interest in intervac, l.l.c., a maryland limited liability company, which in turn beneficially owns an aggregate of 2,172,125 shares of common stock. the reporting person expressly disclaims beneficial ownership of any shares of common stock owned by intervac, l.l.c., except to the extent of his pecuniary interest therein.
f4 the reporting person holds individually and with his wife, as tenants by the entirety, an aggregate 89.2% equity interest in biovac, l.l.c. biovac, l.l.c. is the direct owner of 762,077 shares of common stock. the reporting person disclaims beneficial ownership of the shares of common stock directly owned by biovac, l.l.c., except to the extent of his pecuniary interest therein.

Elevate your investments